Relief Therapeutics (OTCQB:RLFTY) has announced a significant business combination with NeuroX, the successor company to MindMaze, through a binding term sheet. The transaction values Relief at CHF 100 million and NeuroX at CHF 1 billion. Post-merger, Relief shareholders will own approximately 9% of the combined entity, while NeuroX shareholders will hold 91%.
NeuroX, which recently acquired MindMaze's assets and operations, brings a clinically validated portfolio of AI-based digital neurotherapeutics for treating neurological diseases and brain disorders. The company has invested over $350 million in developing its platform, which combines software-delivered behavioral treatments with drugs, devices, and AI technology.
The transaction is expected to close in Q4 2025, subject to customary conditions including shareholder approvals, due diligence, and regulatory clearances
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.